Drug profile · INN
dibucaine hydrochloride
HEAVY SOLUTION NUPERCAINE
dibucaine hydrochloride (HEAVY SOLUTION NUPERCAINE) is a sodium channel protein type v alpha subunit blocker. Route of administration: injection. Current US regulatory status: approved.
Drug details — dibucaine hydrochloride
- US status
- approved
- Class
- —
- Route
- INJECTION
- Patents
- 0
- Programs
- 0
- Data quality
- 0.84
Quick answer
dibucaine hydrochloride (HEAVY SOLUTION NUPERCAINE) is a sodium channel protein type v alpha subunit blocker. Route of administration: injection. Current US regulatory status: approved.
Key facts
Mechanism of action
Sodium channel protein type V alpha subunit blocker
Primary target: Sodium channel protein type 5 subunit alpha
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is dibucaine hydrochloride?
dibucaine hydrochloride (HEAVY SOLUTION NUPERCAINE) is a sodium channel protein type v alpha subunit blocker. Route of administration: injection. Current US regulatory status: approved.
What is the brand name for dibucaine hydrochloride?
HEAVY SOLUTION NUPERCAINE is a marketed brand name for dibucaine hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of dibucaine hydrochloride?
dibucaine hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.